Sol-Gel Technologies Reports Second Quarter 2020 Financial Results and Corporate Update
New Drug Application for Epsolay® Submitted; Twyneo® New Drug Application on track for 2H 2020 Top-line generic product revenue of $1.1 million in 2Q 2020 Launch of additional generic product expected in 2Q 2021 NESS ZIONA, Israel, Aug. 06, 2020 (GLOBE …